comparemela.com

Latest Breaking News On - Autoimmunity reviews - Page 4 : comparemela.com

Rare Disease Genetic Testing Market is Driven by Rise in Awareness Regarding Disease Prevention – KSU

Rare Disease Genetic Testing Market is Driven by Rise in Awareness Regarding Disease Prevention tmrMay 13, 2021 Rare Disease Genetic Testing: Introduction More than 7000 types of rare diseases affect more than 30 million people in the U.S. alone. Approximately 80% of the rare diseases are found to be genetic. Genetic testing is an advanced diagnostic tool that not only helps to identify the exact disease manifestations but also determine the underlying causes of genetic disorders Genetic testing offers various benefits including confirming a diagnosis, understanding the cause of unexplained symptoms, and identifying treatment options including clinical trials Key Drivers and Restraints of Global Rare Disease Genetic Testing Market

10 Natural Remedies for Psoriatic Arthritis

iStock With a condition as complicated as psoriatic arthritis, finding a natural therapy that has been well researched (never mind proven to be effective) is a challenge. That said, it’s understandable that you would want to investigate natural ingredients and home remedies for psoriatic arthritis. A few words of caution: Always talk to your doctor before trying any new therapy, including “natural” ones, and ask exactly what dosage is appropriate. Dietary supplements are not regulated in the same way as prescription drugs, and the potency and purity of different brands can vary. Possible side effects are another concern, particularly when you combine supplements, use them in conjunction with prescription medication, or apply them directly to inflamed skin.

Ilaris® receives Health Canada approval as first of its kind treatment for rare, inflammatory disorder, adult-onset Still s disease

Share this article Share this article The approval of Ilaris (canakinumab) in the treatment of adult-onset Still s disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening inflammatory disorder. Ilaris, an interleukin-1 beta inhibitor, provides a new mode of treatment for this disease  which previously had limited options. 1,2 DORVAL, QC, April 29, 2021 /CNW Telbec/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Ilaris ®  (canakinumab) for the treatment of active Still s disease, including adult-onset Still s disease (AOSD) 1. AOSD is a rare form of inflammatory arthritis that can be a complex disease with variable presentation and potentially life-threatening complications

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.